	Application No.	Applicant(s)
Notice of Allowability	10/080,874	WALKER ET AL.
	Examiner	Art Unit
	Stephen Gucker	1649
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to	oplication. If not included n will be mailed in due course. THIS
1. X This communication is responsive to 7/13/05.		•
2. The allowed claim(s) is/are 14, renumbered as claim 1.		
3. The drawings filed on 22 February 2002 are accepted by the	ne Examiner.	
 4. Acknowledgment is made of a claim for foreign priority unall	e been received. been received in Application No. On the communication to file a reply selected the selection.	national stage application from the complying with the requirements
INFORMAL PATENT APPLICATION (PTO-152) which give		
 CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftspers hereto or 2) to Paper No./Mail Date including changes required by the attached Examiner's Paper No./Mail Date Identifying Indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the deposit of the deposit	son's Patent Drawing Review (PTO s Amendment / Comment or in the (.84(c)) should be written on the drawing the header according to 37 CFR 1.121(sit of BIOLOGICAL MATERIAL	Office action of ings in the front (not the back) of (d). must be submitted. Note the
	•	·
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of Informal F	Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	(PTO-413).
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 	Paper No./Mail Da 8), 7. 🖾 Examiner's Amend	ment/Comment PAPER
4. Examiner's Comment Regarding Requirement for Deposit	8. X Examiner's Statem	ent of Reasons for Allowance
of Biological Material	9. Other JAI SUPERVISE	NET L ANDRES ORY PATENT EXAMINER



Application/Control Number: 10/080,874

Art Unit: 1649

EXAMINER'S AMENDMENT & REASONS FOR ALLOWANCE

- 1. The Art Unit location of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1649.
- 2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Michelle A. Klein and Thomas J. Kowalski on 8/10/05.

An examiner's amendment to the record appears below.

In the specification:

Page 1, line 2, deleted "allowed" and "Application Serial".

Page 1, line 2, after "U.S." inserted: --Patent--.

Page 1, line 3, deleted "09/029,535,".

Page 1, line 3, before "filed" inserted: --6,368,816--.

Page 1, line 7, deleted "Application Serial" and "09/029,535".

Page 1, line 7, before "No." inserted: --Patent--.

Page 1, line 7, after "No." inserted: --6,368,816--.

Page 1, line 9, deleted "Attorney docket numbers 674543-2001.2, 674543-2001.4,".

Page 1, line 9, inserted after "assigned, (":

-- U.S. Application Serial No. 10/080,875, U.S. Patent No. 6,838,253--.

Application/Control Number: 10/080,874 Page 3

Art Unit: 1649

Page 1, line 10, deleted "674543-2001.5 and 674543-2001.6).".

Page 1, line 10, inserted: --U.S. Application Serial Nos. 10/081,787 and 10/080,876).--.

In the claims:

In claim 14, line 3, deleted: "a human or"

3. The following is an examiner's statement of reasons for allowance: the closest prior art of record was Lakshmi et al. and Gomez-Sanchez et al. The instant claim has been amended to recite that the instant method be performed by using neuronal whole cells in culture (for support, see the specification at page 20, lines 33-35, and page 22, line 2, for example) which excludes both Lakshmi et al. and Gomez-Sanchez et al. as being anticipatory prior art references. Furthermore, the prior art of record does not fairly suggest the instant invention because of the unexpected result disclosed by the instant application that the 11-Beta HSD1 exhibits only reductase activity in whole cells, but exhibits both dehydrogenase and reductase activity in tissue homogenates or in its isolated form (see pages 21-22 of the specification). Because of the unidirectionality of the enzyme reaction in neuronal whole cells, as opposed to bidirectionality that has already been observed *in vitro*, the instant method has clinical utility as discussed in the specification on page 22.

Application/Control Number: 10/080,874 Page 4

Art Unit: 1649

`Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

4. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technical Center 1600 general number which is (571) 272-1600.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen Gucker whose telephone number is (571) 272-0883. The examiner can normally be reached on Monday to Friday from 0930 to 1800. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached at (571) 272-0867. The fax phone number for this Group is currently (571)-273-8300.

Stephen Gucker

August 12, 2005